RXRX

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $4.03, moving 4.95% from the previous trading session.

Key TakeawaysAbsci fell 8% today as AI drug discovery peers Schrödinger and Recursion slid in a Nasdaq sell-off. These stocks trade together on sentiment, so the drop says little about Absci’s business.

RXRX heads into Q3 earnings with key collaboration milestones, advancing clinical programs and upcoming pipeline updates that could shape its outlook.

Recursion Pharmaceuticals (RXRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.8, signifying a +2.7% move from its prior day's close.

Recursion Pharmaceuticals (RXRX) reached $3.66 at the closing of the latest trading day, reflecting a +1.39% change compared to its last close.

Recursion Pharmaceuticals has had a rough ride on the market lately, and the slide raises a simple question for investors who still like the story around its platform and partnerships.

Recursion Pharmaceuticals reported past pipeline and collaboration progress, including positive REC-4881 and REC-1245 trial updates and Sanofi optioning a development candidate that triggered a US$10 million milestone within a broader US$144 million received…

Recursion Pharmaceuticals (RXRX) just moved onto many investors’ radar after Sanofi optioned the first development candidate from their collaboration, triggering a US$10 million milestone payment and shifting future economics for that program.

Recursion Pharmaceuticals is back in focus after analysts adjusted their price target to US$5.90, following earlier updates at US$5.50 and US$5.30.

Recursion Pharmaceuticals (NasdaqGS:RXRX) said Sanofi has exercised its option on the first immunology candidate in their collaboration, triggering a milestone payment.